Date set for appeal by ex-doctor in Vegas hepatitis C case
LAS VEGAS (AP) - The Nevada Supreme Court is scheduling oral arguments April 5 on an appeal by a once-prominent Las Vegas doctor serving 18 years to life in prison for the largest hepatitis C outbreak in state history. Attorneys for Dipak Desai argue ...
KOLO - Sun, 07 Feb 2016 04:11

Date set for appeal by ex-doctor in hepatitis C case
News3LV - Sun, 07 Feb 2016 04:11



Lawsuits claim insurers unfairly refuse pricey hepatitis C drugs
The complaints allege that two Washington state insurers - Group Health and BridgeSpan insurance, a subsidiary of Regence BlueShield - are unfairly limiting use of hep C drugs based on cost, not medical necessity. Some insurers in the state cover ...
Houston Chronicle - Sat, 06 Feb 2016 16:22



Lawmaker: Costly hepatitis C drug "a slap in the face to the veterans"
A Congressional hearing will begin Wednesday in response to a CBS News investigation that showed how a costly new cure for hepatitis C isn't making it to most of the 200,000 U.S. veterans infected with the disease, many as a result of their service.
CBS News - Wed, 03 Feb 2016 04:05



Congress outraged over hepatitis C treatment VA can't afford
Their target is Dr. Raymond Schinazi, who played a leading role developing a drug that cures hepatitis C. When he sold his company to pharmaceutical giant Gilead in 2012, he made over $400 million. And he did it all while working seven-eighths of his ...
CBS News - Wed, 03 Feb 2016 16:22

House: VA gouged on hep C miracle drug it developed
FedScoop - Wed, 03 Feb 2016 15:18



California Pays Insurers Millions More For Hepatitis C Drugs
Private health plans invoiced the state of California $387.5 million to cover high-cost hepatitis C treatments in Medi-Cal between July 2014 and November 2015, when just 3,624 patients received the treatments, according to the California Department of ...
NPR - Thu, 28 Jan 2016 12:09

California Doles Out Millions to Insurers for Hepatitis C Drugs
KQED - Wed, 27 Jan 2016 16:56



Hep C Drug 'Price War' Looming
Health experts are predicting a "price war" is looming over expensive hepatitis C drugs taken by many older Americans to treat the virus. Merck announced a list price of $54,000 for a 12-week course of Zepatier — a price significantly lower than two ...
Newsmax - Fri, 05 Feb 2016 11:18

FDA approves new combination product to treat chronic hepatitis C infection
The Pharmaceutical Journal - Thu, 04 Feb 2016 08:18

Merck Obtains Approval of ZEPATIERâ„¢ in Canada for the Treatment of Chronic ...
Investing News Network (press release) (registration) (blog) - Thu, 04 Feb 2016 09:54



Swedish Hospital patients being tested for Hep B, Hep C, HIV
Roughly 2,900 people who had surgery at Swedish Medical Center the past five months are being notified that they need to be tested for HIV, hepatitis B and hepatitis C as part of an investigation into a now-former surgical technician. 9NEWS at 9 p.m. 02/0.
9NEWS.com - Wed, 03 Feb 2016 11:33

Swedish Medical Center patients at risk of HIV, hepatitis B, hepatitis C
HealthLeaders Media - Wed, 03 Feb 2016 22:56

2900 patients at Colorado hospital may have been exposed to HIV, hepatitis B ...
New York Daily News - Wed, 03 Feb 2016 16:28

Ex-employee may have exposed Swedish Medical Center patients to HIV, hepatitis ...
FOX31 Denver - Wed, 03 Feb 2016 12:37

Colorado hospital: Patients may be at risk for hepatitis, HIV
CNN - Wed, 03 Feb 2016 16:45

Swedish Medical Center says federal, state agencies recommended tests
The Denver Post - Thu, 04 Feb 2016 17:04



Merck & Co joins hepatitis C party
The US Food and Drug Administration has approved a new combination hepatitis C (HCV) treatment from US firm Merck & Co. Zepatier (elbasvir and grazoprevir) joins the growing family of new drugs that can cure the disease without the use of interferon, ...
Royal Society of Chemistry - Mon, 01 Feb 2016 02:22

In-depth Merck release on new Hep C drug skirts some of the basics
HealthNewsReview.org - Tue, 02 Feb 2016 09:34

FDA Approves Zepatier for Treatment of Chronic Hepatitis C Genotypes 1 and 4
Infection Control Today - Mon, 01 Feb 2016 07:10

Hep C market poised for pricing rumble as Merck's cheaper med approved
BioPharma Dive - Mon, 01 Feb 2016 07:56

FDA OKs Merck Hepatitis C Drug, Adding to Patient Choices
Sci-Tech Today - Sun, 31 Jan 2016 19:22

Zepatier Approved as Hep C Treatment
Pharmacy Times - Tue, 02 Feb 2016 04:08

FDA approves Zepatier for hepatitis C genotypes 1 and 4
Clinical Advisor - Mon, 01 Feb 2016 11:41


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014